Long pages

Jump to navigation Jump to search

Showing below up to 50 results in range #101 to #150.

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

  1. (hist) ‎Conclusion (Section from DOI: 10.1080/09273948.2020.1738501) ‎[2,284 bytes]
  2. (hist) ‎SARS-CoV-2: Is it the newest spark in the TORCH? (DOI: 10.1016/j.jcv.2020.104372) ‎[2,271 bytes]
  3. (hist) ‎The Coronavirus Structure and Host (Section from DOI: 10.1080/09273948.2020.1738501) ‎[2,268 bytes]
  4. (hist) ‎Section 1: Introduction (from DOI: 10.1007/s11886-020-01293-2) ‎[2,264 bytes]
  5. (hist) ‎Trends and Prediction in Daily New Cases and Deaths of COVID-19 in the United States: An Internet Search-Interest Based Model ‎[2,214 bytes]
  6. (hist) ‎Section 3: Cardiovascular Comorbidities and COVID-19 Outcomes (from DOI: 10.1007/s11886-020-01293-2) ‎[2,162 bytes]
  7. (hist) ‎Section 5: Conclusions (from DOI: 10.1186/s13054-020-02882-x) ‎[2,155 bytes]
  8. (hist) ‎Section 2: Biology of SARS-CoV-2 (from DOI: 10.1007/s11886-020-01292-3) ‎[2,149 bytes]
  9. (hist) ‎Section 4.3: Targeting the CSC microenvironment (from DOI: 10.1038/s41392-020-0110-5) ‎[2,092 bytes]
  10. (hist) ‎Introduction section from DOI: 10.3390/pathogens9020148 ‎[2,054 bytes]
  11. (hist) ‎The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China (DOI: 10.1186/s13613-020-00653-z) ‎[2,029 bytes]
  12. (hist) ‎Section 2.1: Lessons from animal models (from DOI: 10.1016/j.jcv.2020.104372) ‎[1,995 bytes]
  13. (hist) ‎Section 3.3.5: Cancer-associated MSCs and CSCs (from DOI: 10.1038/s41392-020-0110-5) ‎[1,972 bytes]
  14. (hist) ‎Protection by Exclusion (DOI: 10.1097/AOG.0000000000003924) ‎[1,950 bytes]
  15. (hist) ‎Section 3.4. Whole Viral Genome Sequencing (from DOI: 10.3390/v12020211) ‎[1,947 bytes]
  16. (hist) ‎Section 3.3.2: The hypoxia microenvironment and CSCs (from DOI: 10.1038/s41392-020-0110-5) ‎[1,940 bytes]
  17. (hist) ‎Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response ‎[1,873 bytes]
  18. (hist) ‎Section 4: Protection and transfer (from DOI: 10.1080/22221751.2020.1735265) ‎[1,759 bytes]
  19. (hist) ‎Section 3.3. Methods for Improving Sequencing Output (from DOI: 10.3390/v12020211) ‎[1,741 bytes]
  20. (hist) ‎COVID-19 pathophysiology: A review (DOI: 10.1016/j.clim.2020.108427) ‎[1,739 bytes]
  21. (hist) ‎Current Trends in Diagnostics of Viral Infections of Unknown Etiology (DOI: 10.3390/v12020211) ‎[1,729 bytes]
  22. (hist) ‎Section 3.1.2: Arrhythmia (from DOI: 10.1007/s11886-020-01293-2) ‎[1,711 bytes]
  23. (hist) ‎Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty (DOI: 10.1007/s11886-020-01293-2) ‎[1,689 bytes]
  24. (hist) ‎Section 3.2: Diagnostic criteria (from DOI: 10.1080/22221751.2020.1735265) ‎[1,689 bytes]
  25. (hist) ‎Section 8: Conclusion (from DOI: 10.1007/s11886-020-01292-3) ‎[1,687 bytes]
  26. (hist) ‎Section 3.3: The microenvironment of CSCs (from DOI: 10.1038/s41392-020-0110-5) ‎[1,647 bytes]
  27. (hist) ‎Section 6. Conclusions (from DOI: 10.3390/v12020211) ‎[1,619 bytes]
  28. (hist) ‎Section 4: Conclusion (from DOI: 10.1007/s11886-020-01293-2) ‎[1,609 bytes]
  29. (hist) ‎Section 3.3.6: Extracellular matrix and CSCs (from DOI: 10.1038/s41392-020-0110-5) ‎[1,596 bytes]
  30. (hist) ‎Test Episode ‎[1,584 bytes]
  31. (hist) ‎Section 3. Studying Viral Pathogens with High Throughput Sequencing (HTS) (from DOI: 10.3390/v12020211) ‎[1,580 bytes]
  32. (hist) ‎Section 1: Introduction (from DOI: 10.1016/j.adro.2020.04.015) ‎[1,504 bytes]
  33. (hist) ‎Transcribing Historical Play-by-play Data - RGC Study ‎[1,482 bytes]
  34. (hist) ‎End of 1st Quarter ‎[1,374 bytes]
  35. (hist) ‎End of 2nd Quarter ‎[1,349 bytes]
  36. (hist) ‎End of 3rd Quarter ‎[1,336 bytes]
  37. (hist) ‎Section 1: Introduction (from DOI: 10.1080/22221751.2020.1735265) ‎[1,326 bytes]
  38. (hist) ‎Section 3.1: Cardiac Complications of COVID-19 (from DOI: 10.1007/s11886-020-01293-2) ‎[1,312 bytes]
  39. (hist) ‎Section 3.4.1: Severe type (from DOI: 10.1080/22221751.2020.1735265) ‎[1,311 bytes]
  40. (hist) ‎Section 2.3: Isolation and observation of medical personnel after close contact with SARS-CoV-2 (from DOI: 10.1080/22221751.2020.1735265) ‎[1,301 bytes]
  41. (hist) ‎Wikibase Techniques and To Do List ‎[1,267 bytes]
  42. (hist) ‎Section 3.3.2: Sequential examination of confirmed patients (from DOI: 10.1080/22221751.2020.1735265) ‎[1,250 bytes]
  43. (hist) ‎Section 2: IFNs as natural broad-spectrum antivirals (from DOI: 10.1084/jem.20200653) ‎[1,233 bytes]
  44. (hist) ‎Section 1: Introduction (from DOI: 10.1084/jem.20200653) ‎[1,223 bytes]
  45. (hist) ‎Prosopography Bibliography ‎[1,221 bytes]
  46. (hist) ‎Section 3: Factors regulating CSCs (from DOI: 10.1038/s41392-020-0110-5) ‎[1,217 bytes]
  47. (hist) ‎Section 2.1: Selection of front-line personnel (from DOI: 10.1080/22221751.2020.1735265) ‎[1,208 bytes]
  48. (hist) ‎Section 3.5.2.2: The way of respiratory support (from DOI: 10.1080/22221751.2020.1735265) ‎[1,186 bytes]
  49. (hist) ‎Section 1: Introduction (from DOI:10.14218/ERHM.2020.00023) ‎[1,139 bytes]
  50. (hist) ‎COVID-19 and emerging viral infections: The case for interferon lambda (DOI: 10.1084/jem.20200653) ‎[1,100 bytes]

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://wikibase.slis.ua.edu/wiki/Special:LongPages"